{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:42Z","timestamp":1790096922999,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104793","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:17:29Z","timestamp":1788362249000},"page":"104793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From diligence to verification: the emergence of the TechBio-Investor"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7197-104X","authenticated-orcid":false,"given":"Robert","family":"Vandersluis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104793_b0005","first-page":"36","article-title":"Biotech asset valuation methods: a practitioner\u2019s guide","volume":"22","author":"Chandra","year":"2024","journal-title":"J Invest Manag"},{"key":"10.1016\/j.drudis.2026.104793_b0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104793_b0015","article-title":"The AI Scientist: towards fully automated open-ended scientific discovery","author":"Lu","year":"2024","journal-title":"arXiv"},{"key":"10.1016\/j.drudis.2026.104793_b0020","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1016\/j.cell.2024.09.022","article-title":"Empowering biomedical discovery with AI agents","volume":"187","author":"Gao","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104793_b0025","article-title":"Towards an AI Co-Scientist","author":"Gottweis","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.drudis.2026.104793_b0030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41586-025-09442-9","article-title":"The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies","volume":"646","author":"Swanson","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104793_b0035","unstructured":"MIT Technology Review. Claude Science is Anthropic\u2019s newest flagship product. Published 30 June 2026. Accessed 16 August 2026. https:\/\/www.technologyreview.com\/2026\/06\/30\/1139987\/claude-science-is-anthropics-newest-flagship-product\/."},{"key":"10.1016\/j.drudis.2026.104793_b0040","article-title":"LLM-based agents for competitive landscape mapping in drug asset due diligence","author":"Vinogradova","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.drudis.2026.104793_b0045","unstructured":"Vivodyne Partnerships. Vivodyne website. Accessed 16 August 2026. https:\/\/www.vivodyne.com\/partnerships."},{"key":"10.1016\/j.drudis.2026.104793_b0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.drudis.2026.104793_b0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cbpa.2006.06.022","article-title":"Streamlining lead discovery by aligning in silico and high-throughput screening","volume":"10","author":"Davies","year":"2006","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2026.104793_b0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/2472555220949495","article-title":"Changing the HTS paradigm: AI-driven iterative screening for hit finding","volume":"26","author":"Dreiman","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2026.104793_b0065","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104793_b0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14737167.2025.2507426","article-title":"Economic and developmental impacts of FDA designations: a systematic review and meta-analysis","volume":"25","author":"Williamson","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.drudis.2026.104793_b0075","article-title":"The refutability gap: challenges in validating reasoning by large language models","author":"Mossel","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.drudis.2026.104793_b0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-405X(87)90042-0","article-title":"Constraints on short-selling and asset price adjustment to private information","volume":"18","author":"Diamond","year":"1987","journal-title":"J Financ Econ"},{"key":"10.1016\/j.drudis.2026.104793_b0085","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1540-6261.2010.01597.x","article-title":"Short sellers and financial misconduct","volume":"65","author":"Karpoff","year":"2010","journal-title":"J Finance"},{"key":"10.1016\/j.drudis.2026.104793_b0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.aax2342","article-title":"Dissecting racial bias in an algorithm used to manage the health of populations","volume":"366","author":"Obermeyer","year":"2019","journal-title":"Science"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:19:10Z","timestamp":1790093950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001984"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104793","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From diligence to verification: the emergence of the TechBio-Investor","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104793"}}